Literature DB >> 25053418

Glucose directly promotes antifungal resistance in the fungal pathogen, Candida spp.

Santi M Mandal1, Denial Mahata2, Ludovico Migliolo3, Aditya Parekh2, Partha S Addy2, Mahitosh Mandal2, Amit Basak4.   

Abstract

Effects of glucose on the susceptibility of antifungal agents were investigated against Candida spp. Increasing the concentration of glucose decreased the activity of antifungal agents; voriconazole was the most affected drugs followed by amphotericin B. No significant change has been observed for anidulafungin. Biophysical interactions between antifungal agents with glucose molecules were investigated using isothermal titration calorimetry, Fourier transform infrared, and (1)H NMR. Glucose has a higher affinity to bind with voriconazole by hydrogen bonding and decrease the susceptibility of antifungal agents during chemotherapy. In addition to confirming the results observed in vitro, theoretical docking studies demonstrated that voriconazole presented three important hydrogen bonds and amphotericin B presented two hydrogen bonds that stabilized the glucose. In vivo results also suggest that the physiologically relevant higher glucose level in the bloodstream of diabetes mellitus mice might interact with the available selective agents during antifungal therapy, thus decreasing glucose activity by complex formation. Thus, proper selection of drugs for diabetes mellitus patients is important to control infectious diseases.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Antibiotic Resistance; Candida albicans; Diabetes; Drug Action; Glucose

Mesh:

Substances:

Year:  2014        PMID: 25053418      PMCID: PMC4162151          DOI: 10.1074/jbc.C114.571778

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Anti-infectious activity of intravitreal injectable voriconazole microspheres on experimental rabbit fungal endophthalmitis caused by Aspergillus fumigatus.

Authors:  Wu Xiang-Gen; Yang Li-Na; Xin Meng; Jiang Hao-Ran
Journal:  J Pharm Sci       Date:  2010-11-24       Impact factor: 3.534

2.  Prevalence of Candida in the oral cavity of diabetic subjects.

Authors:  B V Kumar; N S Padshetty; K Y Bai; M S Rao
Journal:  J Assoc Physicians India       Date:  2005-07

3.  Oral candidal carriage and infection in insulin-treated diabetic patients.

Authors:  A M Willis; W A Coulter; C R Fulton; J R Hayes; P M Bell; P J Lamey
Journal:  Diabet Med       Date:  1999-08       Impact factor: 4.359

Review 4.  Candida albicans: genetics, dimorphism and pathogenicity.

Authors:  G Molero; R Díez-Orejas; F Navarro-García; L Monteoliva; J Pla; C Gil; M Sánchez-Pérez; C Nombela
Journal:  Int Microbiol       Date:  1998-06       Impact factor: 2.479

5.  Candidal colonization, strain diversity, and antifungal susceptibility among adult diabetic patients.

Authors:  Safia A Al-Attas; Soliman O Amro
Journal:  Ann Saudi Med       Date:  2010 Mar-Apr       Impact factor: 1.526

6.  Infections in patients with type 2 diabetes in general practice.

Authors:  M L Bartelink; L Hoek; J P Freriks; G E Rutten
Journal:  Diabetes Res Clin Pract       Date:  1998-04       Impact factor: 5.602

7.  Glucose promotes stress resistance in the fungal pathogen Candida albicans.

Authors:  Alexandra Rodaki; Iryna M Bohovych; Brice Enjalbert; Tim Young; Frank C Odds; Neil A R Gow; Alistair J P Brown
Journal:  Mol Biol Cell       Date:  2009-09-16       Impact factor: 4.138

8.  N, N'-Olefin functionalized bis-imidazolium gold(I) salt is an efficient candidate to control keratitis-associated eye infection.

Authors:  Tapastaru Samanta; Gourisankar Roymahapatra; William F Porto; Saikat Seth; Sudipta Ghorai; Suman Saha; Jayangshu Sengupta; Octávio L Franco; Joydev Dinda; Santi M Mandal
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

9.  Bloodstream infections at a Norwegian university hospital, 1974-1979 and 1988-1989: changing etiology, clinical features, and outcome.

Authors:  J B Haug; S Harthug; T Kalager; A Digranes; C O Solberg
Journal:  Clin Infect Dis       Date:  1994-08       Impact factor: 9.079

10.  Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative medium.

Authors:  Mahomed-Yunus S Moosa; Jack D Sobel; Hussain Elhalis; Wenjin Du; Robert A Akins
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more
  6 in total

1.  Estimation of Candida albicans ABC Transporter Behavior in Real-Time via Fluorescence.

Authors:  Joanna Szczepaniak; Marcin Łukaszewicz; Anna Krasowska
Journal:  Front Microbiol       Date:  2015-12-09       Impact factor: 5.640

2.  Influence of culture media on biofilm formation by Candida species and response of sessile cells to antifungals and oxidative stress.

Authors:  Isela Serrano-Fujarte; Everardo López-Romero; Georgina Elena Reyna-López; Ma Alejandrina Martínez-Gámez; Arturo Vega-González; Mayra Cuéllar-Cruz
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

3.  Fructose Induces Fluconazole Resistance in Candida albicans through Activation of Mdr1 and Cdr1 Transporters.

Authors:  Jakub Suchodolski; Anna Krasowska
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

4.  Prevalence and antifungal susceptibility of gastrointestinal candidiasis among diabetic patients: A cross-sectional study.

Authors:  Anthony P Oyom; Emmanuel Okello; Victoria Acam; Christine Aramo; Bashir Mwambi; John C Okiria; Caesar Oyet
Journal:  Afr J Lab Med       Date:  2020-12-10

5.  Impact of host factors on susceptibility to antifungal agents.

Authors:  Balbina Plotkin; Monika Konaklieva
Journal:  ADMET DMPK       Date:  2022-01-07

Review 6.  Adapting to survive: How Candida overcomes host-imposed constraints during human colonization.

Authors:  Rosana Alves; Cláudia Barata-Antunes; Margarida Casal; Alistair J P Brown; Patrick Van Dijck; Sandra Paiva
Journal:  PLoS Pathog       Date:  2020-05-21       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.